{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Heron Therapeutics, Inc.  "},"Symbol":{"label":"Symbol","value":"HRTX"},"Address":{"label":"Address","value":"4242 CAMPUS POINT COURT,SUITE 200, SAN DIEGO, California, 92121, United States"},"Phone":{"label":"Phone","value":"+1 858 251-4400"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011."},"CompanyUrl":{"label":"Company Url","value":"https://www.herontx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Chris M. Storgard","title":"Chief Medical Officer"},{"name":"Craig A. Collard","title":"Chief Executive Officer & Director"},{"name":"Thomas B. Ottoboni","title":"Chief Scientific Officer & SVP-Pharmaceutical"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}